摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(2-氨基乙基)-5-氯-8-异喹啉磺酰胺 | 120615-25-0

中文名称
N-(2-氨基乙基)-5-氯-8-异喹啉磺酰胺
中文别名
——
英文名称
CKI-7
英文别名
N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulfonamide
N-(2-氨基乙基)-5-氯-8-异喹啉磺酰胺化学式
CAS
120615-25-0
化学式
C11H12ClN3O2S
mdl
——
分子量
285.754
InChiKey
OGKYMFFYOWUTKV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    188-190°C
  • 沸点:
    499.7±55.0 °C(Predicted)
  • 密度:
    1.432±0.06 g/cm3(Predicted)
  • 溶解度:
    H2O:9 mg/mL

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    93.5
  • 氢给体数:
    2
  • 氢受体数:
    5

安全信息

  • 危险品标志:
    T
  • 危险类别码:
    R25
  • 危险品运输编号:
    UN 2811 6.1/PG 3
  • WGK Germany:
    3
  • 海关编码:
    2935009090
  • 安全说明:
    S45

制备方法与用途

生物活性

CKI-7 free base 是一种有效且 ATP 竞争性的酪蛋白激酶 1 (CK1) 抑制剂,IC50 值为 6 μM,Ki 值为 8.5 μM。除了选择性抑制 Cdc7 激酶外,它还抑制 SGK、S6K1 和 MSK1。对酪蛋白激酶 II 及其他蛋白激酶的作用则较弱。

靶点
酪蛋白激酶 1 (CK1) 6 μM (IC50)
酪蛋白激酶 1 (CK1) 8.5 μM (Ki)
Cdc7
SGK
S6K1
MSK1
体外研究

在 ES 细胞中,使用 CKI-7(0.1-10 μM;5 天)处理显著增加了早期神经胚层标记物 Sox1 的表达,并且以浓度依赖的方式增加了巢蛋白和 βIII-微管蛋白阳性细胞的数量。另外,在 ES 细胞中使用 5 μM 的 CKI-7 (5 天) 处理抑制了 SFEB 引起的 β-catenin 稳定化,表明 CKI-7 抑制 Wnt 信号通路。

实验方法 细胞系 浓度 (μM) 培养时间(天) 结果
RT-PCR 小鼠 ES 细胞 0.1-10 5 在浓度依赖的方式下显著增加了早期神经胚层标记物 Sox1 的表达,并且增加了巢蛋白和 βIII-微管蛋白阳性细胞的数量。
蛋白印迹分析 小鼠 ES 细胞 5 5 抑制了 SFEB 引起的 β-catenin 稳定化,在第 5 天时表现出这种效应。
体内研究

在 SCID-Beige 小鼠全身肿瘤模型中,使用最近分离出的费城染色体阳性急性淋巴细胞白血病细胞系证实了 CKI-7 的剂量依赖性抗肿瘤活性。标准细胞周期同步研究表明,CKI-7 处理会导致 caspase 3 依赖性的细胞周期相关凋亡细胞死亡。

反应信息

  • 作为反应物:
    描述:
    N-(2-氨基乙基)-5-氯-8-异喹啉磺酰胺 生成 N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide;hydrochloride
    参考文献:
    名称:
    HIDAKA, HIROYOSHI;TANAKA, TOSHIO;ITOH, YASUO;KATO, HIDEO;KOSHINAKA, EIICH+
    摘要:
    DOI:
  • 作为产物:
    描述:
    N-(2-benzyloxycarbonylaminoethyl)-5-chloroisoquinoline-8-sulfonamide 在 盐酸 作用下, 以 乙醇溴化氢 为溶剂, 生成 N-(2-氨基乙基)-5-氯-8-异喹啉磺酰胺
    参考文献:
    名称:
    Isoquinolinesulfonamides
    摘要:
    本发明公开了一种从下述式子所代表的化合物中选择的异喹啉磺酰胺:##STR1## 其中,R.sub.1、R.sub.2和R.sub.3可以相同也可以不同,且每个表示氢或低碳基,X表示氢或卤素,以及其药理学上可接受的酸加盐,制备的制药组合物,以及在治疗循环障碍方面的应用。
    公开号:
    US04943581A1
点击查看最新优质反应信息

文献信息

  • METHOD FOR INDUCTION/DIFFERENTIATION INTO PHOTORECEPTOR CELL
    申请人:Riken
    公开号:EP2128244A1
    公开(公告)日:2009-12-02
    The present invention provides a method of producing primate retinal progenitor cells, comprising culturing primate embryonic stem cells as suspended aggregates in a serum-free medium, and obtaining retinal progenitor cells from the culture. The present invention further provides a method of producing photoreceptor precursor cells, comprising culturing isolated retinal progenitor cells differentiated from embryonic stem cells, under adhesive conditions, in the presence of a gamma secretase inhibitor, and obtaining a photoreceptor precursor from the culture.
    本发明提供了一种生产灵长类动物视网膜祖细胞的方法,包括在无血清培养基中培养悬浮聚集的灵长类动物胚胎干细胞,并从培养物中获得视网膜祖细胞。本发明进一步提供了一种生产光感受器前体细胞的方法,包括在γ分泌酶抑制剂存在下,在粘附条件下培养从胚胎干细胞分化而来的分离视网膜祖细胞,并从培养物中获得光感受器前体细胞。
  • Advanced drug development and manufacturing
    申请人:Los Alamos National Security, LLC
    公开号:EP2511844A2
    公开(公告)日:2012-10-17
    There is described an apparatus for measuring protein characteristics comprising an X-ray fluorescence (XRF) spectrometer comprising a source of polychromatic X-rays, an X-ray detector, a protein, a molecule that has been exposed to and at least weakly binds to the protein, a plurality of X-ray fluorescence signal data obtained by irradiating chemical elements in the protein and molecule with the polychromatic X-rays and a security system for maintaining records for the data from the plurality of X-ray fluorescence signal measurements. There is also described an x-ray microscope for measuring a sample.
    描述了一种测量蛋白质特性的仪器,该仪器包括一个 X 射线荧光 (XRF) 光谱仪,其中包括一个多色 X 射线源、一个 X 射线探测器、一个蛋白质、一个已暴露于该蛋白质并至少与该蛋白质弱结合的分子、通过用多色 X 射线照射蛋白质和分子中的化学元素而获得的多个 X 射线荧光信号数据,以及一个用于维护多个 X 射线荧光信号测量数据记录的安全系统。此外,还介绍了一种用于测量样品的 X 射线显微镜。
  • METHODS FOR PRODUCING RETINAL TISSUE AND RETINA-RELATED CELL
    申请人:Sumitomo Chemical Company, Limited
    公开号:EP2784152A1
    公开(公告)日:2014-10-01
    The present invention provides [1] a method for producing a retinal tissue, including the following steps (1) to (3): (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium containing a substance inhibiting the Wnt signal pathway to form an aggregate of pluripotent stem cells, (2) a second step of subjecting the aggregate formed in the first step to floating culture in a serum-free medium containing a basement membrane preparation, and (3) a third step of subjecting the aggregate cultured in the second step to floating culture in a serum-containing medium; [2] a method for producing an optic-cup-like structure, including a step of subjecting an aggregate containing the retinal tissue cultured in the step (3) above to floating culture in a serum-free medium or serum-containing medium each containing a substance acting on the Sonic hedgehog signal pathway and a substance acting on the Wnt signal pathway; [3] a method for producing a retinal pigment epithelium, including a step of subjecting an aggregate containing the retinal tissue cultured in the step (3) above to floating culture in a serum-free medium or serum-containing medium each containing a substance acting on the Wnt signal pathway (wherein said serum-free medium and serum-containing medium are free of a substance acting on the Sonic hedgehog signal pathway); and [4] a method for producing a retinal layer-specific neural cell, including bringing a retinal progenitor cell contained in a retinal tissue derived from a primate pluripotent stem cell into contact with a substance inhibiting the Notch signal pathway.
    本发明提供 [1]一种生产视网膜组织的方法,包括以下步骤(1)至(3): (1) 第一步,将多能干细胞置于含有抑制 Wnt 信号通路的物质的无血清培养基中进行漂浮培养,以形成多能干细胞聚集体、 (2) 第二步,将第一步中形成的聚集体置于含有基底膜制剂的无血清培养基中进行漂浮培养,以及 (3) 第三步,将第二步培养出的聚合体置于含血清培养基中进行漂浮培养; [2]一种生产视杯样结构的方法,包括以下步骤:将含有在上述步骤(3)中培养的视网膜组织的集合体置于无血清培养基或含血清培养基中进行漂浮培养,每种培养基都含有一种作用于Sonic hedgehog信号通路的物质和一种作用于Wnt信号通路的物质; [3]一种生产视网膜色素上皮细胞的方法,包括以下步骤:将含有在上述步骤(3)中培养的视网膜组织的集合体置于无血清培养基或含血清培养基中进行漂浮培养,每种培养基均含有作用于Wnt信号通路的物质(其中所述无血清培养基和含血清培养基不含作用于声子刺猬信号通路的物质);以及 [4]一种生产视网膜层特异性神经细胞的方法,包括使来源于灵长类多能干细胞的视网膜组织中含有的视网膜祖细胞与抑制Notch信号通路的物质接触。
  • METHOD FOR PRODUCING CILIARY MARGINAL ZONE-LIKE STRUCTURE
    申请人:Sumitomo Chemical Co., Ltd
    公开号:EP2860245A1
    公开(公告)日:2015-04-15
    The present invention provides a method for producing a cell aggregate containing a ciliary marginal zone-like structure, including a step of culturing a cell aggregate containing a retinal tissue in which Chx10 positive cells are present in a proportion of 20% or more of the tissue in a serum-free medium or serum-containing medium each containing a substance acting on the Wnt signal pathway for only a period before the appearance of a RPE65 gene expressing cell, followed by culturing the "cell aggregate in which a RPE65 gene expressing cell does not appear" thus obtained in a serum-free medium or serum-containing medium each not containing a substance acting on the Wnt signal pathway and so on. According to the present invention, a ciliary marginal zone-like structure can be produced with high efficiency.
    本发明提供了一种生产含有睫状边缘区样结构的细胞聚集体的方法,包括以下步骤:在RPE65基因表达细胞出现之前的一段时间内,在无血清培养基或含血清培养基中培养含有视网膜组织的细胞聚集体,其中Chx10阳性细胞的比例为组织的20%或更多、然后将由此获得的 "未出现 RPE65 基因表达细胞的细胞聚集体 "在不含 Wnt 信号通路物质的无血清培养基或含血清培养基中进行培养,依此类推。 根据本发明,可以高效率地生产出类似睫状边缘区的结构。
  • METHOD FOR MANUFACTURING CILIARY MARGINAL ZONE-LIKE STRUCTURE
    申请人:Sumitomo Chemical Company, Limited
    公开号:EP3081637A1
    公开(公告)日:2016-10-19
    The present invention provides a method for producing a cell aggregate containing a ciliary marginal zone-like structure, including a step of culturing a cell aggregate containing a retinal tissue in which Chx10 positive cells are present in a proportion of 20% or more and 100% or less of the tissue in a serum-free medium or serum-containing medium each containing a substance acting on the Wnt signal pathway and a substance inhibiting the FGF signal pathway for only a period before the appearance of a RPE65 gene expressing cell, followed by culturing the "cell aggregate in which a RPE65 gene-expressing cell does not appear" thus obtained in a serum-free medium or serum-containing medium each free of a substance acting on the Wnt signal pathway and so on. According to the production method of the present invention, a ciliary marginal zone-like structure can be produced with high efficiency.
    本发明提供了一种生产含有睫状缘区样结构的细胞聚集体的方法,包括以下步骤:在RPE65基因表达细胞出现之前的一段时间内,在不含血清培养基或含血清培养基中培养含有视网膜组织的细胞聚集体,其中Chx10阳性细胞的比例为20%或以上,100%或以下、然后将由此获得的 "未出现 RPE65 基因表达细胞的细胞聚集体 "在不含 Wnt 信号通路物质的无血清培养基或含血清培养基中进行培养。根据本发明的生产方法,可以高效地生产出睫状缘区样结构。
查看更多